期刊
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 95, 期 7, 页码 3141-3148出版社
ENDOCRINE SOC
DOI: 10.1210/jc.2009-2670
关键词
-
资金
- Novartis
- Italfarmaco
- Ipsen
- Pfizer
- Eli Lilly
- Novo Nordsik
- Sponsored by the Pituitary Society
- European Neuroendocrine Association
Objective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on criteria for cure as defined in 2000. Participants: Participants included 74 neurosurgeons and endocrinologists with extensive experience of treating acromegaly. Evidence/Consensus Process: Relevant assays, biochemical measures, clinical outcomes, and definition of disease control were discussed, based on the available published evidence, and the strength of consensus statements was rated. Conclusions: Criteria to define active acromegaly and disease control were agreed, and several significant changes were made to the 2000 guidelines. Appropriate methods of measuring and achieving disease control were summarized. (J Clin Endocrinol Metab 95: 3141-3148, 2010)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据